# Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

> **NCT00917293** · PHASE2 · TERMINATED · sponsor: **Medicure** · enrollment: 53 (actual)

## Conditions studied

- Tardive Dyskinesia

## Interventions

- **DRUG:** Pyridoxal 5'-Phosphate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00917293
- **Lead sponsor:** Medicure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2012-08
- **Final completion:** 2014-08
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** modified formulation under investigation
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917293, "Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00917293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*